Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration

Keyphrases

• Same-day 100%
• Triple Therapy 100%
• Photodynamic Therapy 100%
• Intravitreal Bevacizumab 100%
• Intravitreal Dexamethasone 100%
• Wet Age-related Macular Degeneration 100%
• Central Macular Thickness 66%
• Baseline Visual Acuity 50%
• Nave 50%
• Intraocular Pressure 33%
• Visual Acuity 33%
• Age-related Macular Degeneration 33%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 33%
• Endophthalmitis 33%
• Previously Treated Patients 33%
• Anti-vascular Endothelial Growth Factor Therapy 33%
• Reduced-fluence Photodynamic Therapy 33%
• Retrospective Case Series 16%
• Previous Treatment 16%
• Optical Coherence Tomography 16%
• Neovascular 16%
• Therapy Treatment 16%
• Neovascular Age-related Macular Degeneration (nAMD) 16%
• Subfoveal 16%
• Macular Thickness 16%

Medicine and Dentistry

• Visual Acuity 100%
• Age Related Macular Degeneration 100%
• Bevacizumab 100%
• Dexamethasone 100%
• Photochemotherapy 100%
• Endothelial Cell Growth Factor 80%
• Intraocular Pressure 40%
• Endophthalmitis 40%
• Optical Coherence Tomography 20%
• Wet Macular Degeneration 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Dexamethasone 100%
• Age Related Macular Degeneration 100%
• Bevacizumab 100%
• Photodynamic Therapy 100%
• Endothelial Cell Growth Factor 100%
• Endophthalmitis 50%
• Wet Macular Degeneration 25%